Novel Medicines for Health Challenges Faced by Millions
At Kallyope, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine and metabolic disorders. Our late-stage pipeline focuses on delivering effective, easy to use, and well-tolerated agents based on novel neural circuits.
Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers.
Our Team
Our accomplished scientists and drug developers bring together agile innovation and real-world focus to create major value for patients.
Our lead candidate is entering pivotal studies for the acute treatment of migraine, and our novel metabolism programs are set to enter clinical studies in mid-2026.
